Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial

Transl Cancer Res. 2023 May 31;12(5):1363-1367. doi: 10.21037/tcr-23-48. Epub 2023 Apr 14.

¹ Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.

No abstract available

Keywords: Recurrent/metastatic squamous cell carcinoma of the head and neck; pembrolizumab; programmed cell death protein 1.

Publication types